je.st
news
Tag: antibody
Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
2014-04-30 07:12:40| drugdiscoveryonline News Articles
Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced today that GBR 900, a novel monoclonal antibody is entering human trials
Tags: human
treatment
pain
entering
01.03.14 -- Five Potential Cancer Targets For Antibody Drug Conjugate Therapy Discovered
2013-12-31 00:29:39| drugdiscoveryonline News Articles
01/03/14Drug Discovery Online Newsletter
Tags: potential
drug
cancer
therapy
Compugen Discloses Discovery Of Five Potential Cancer Targets For Antibody Drug Conjugate Therapy
2013-12-30 05:40:02| drugdiscoveryonline News Articles
Compugen Ltd. recently announced the predictive discovery and selection of five candidate targets for antibody-drug conjugate (ADC) cancer therapy
Tags: potential
drug
cancer
therapy
VivaMab And ADC Therapeutics Announce Antibody Licensing Deal For Novel ADC Candidate To Target Hematologic Cancers
2013-06-24 09:13:00| drugdiscoveryonline News Articles
VivaMab, a therapeutic development division of BioAtla LLC, and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), recently announced a licensing deal for a novel antibody against an undisclosed hematological cancer target
Tags: deal
target
candidate
licensing
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
2013-06-02 17:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. -Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Mercks investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. Language: English Contact HTML: MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
study
presentation